Ocular Therapeutix, Inc. (NASDAQ: OCUL), a leading biopharmaceutical company specializing in innovative eye disease therapies, recently announced its financial results for the second quarter ending on June 30, 2023. Alongside impressive financial performance, the company provided updates on its burgeoning ophthalmology pipeline, showcasing remarkable progress in research and development. Financial Success and Growth Antony Mattessich, […]
